• Immunome presented additional Phase 3 RINGSIDE trial results for investigational varegacestat in progressing desmoid tumors at the 2026 ESMO Congress.
• Patients receiving varegacestat reported lower symptom burden and better physical function than those receiving placebo.
• Previously presented results showed greater tumor response, longer progression-free survival and reduced pain versus placebo; the trial met all key endpoints.
• The most common adverse events included diarrhea, fatigue and rash.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261026171397) on October 26, 2026, and is solely responsible for the information contained therein.